PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Essen University Hospital, The University of Sydney, Melanoma Institute Australia, Aix-Marseille Université, Mount Vernon Cancer Centre, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Novartis (Switzerland), Institut Gustave Roussy, Fondation Gustave Roussy
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4235966785